Back to top
more

Genomic Health, Inc. (GHDX)

(Delayed Data from NSDQ)

$67.55 USD

67.55
321,603

+1.67 (2.53%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.63 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Celgene (CELG) Hits 52-Week High, Can the Run Continue?

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Why the Earnings Surprise Streak Could Continue for Genomic Health (GHDX)

Genomic Health (GHDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Genomic Health (GHDX) Earnings Expected to Grow: Should You Buy?

Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?

During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.

Neena Mishra headshot

Stocks & ETF to Invest in Healthcare Robotics and Innovation

HTEC is poised to benefit from rapid advances in health-care technology

Exact Sciences Gets FDA Nod for Label Expansion of Cologuard

Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.

Neena Mishra headshot

Stocks & ETF to Invest in Healthcare Robotics and Innovation

HTEC is poised to benefit from rapid advances in health-care technology.

Innovation Aids Genomic Health, Merger Procedure on Track

Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.

Why Is Genomic Health (GHDX) Down 0.5% Since Last Earnings Report?

Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Genomic Health Test to Guide Chemo Per New Breast Cancer Rule

This is a major development in Genomic Health's (GHDX) endeavor to strengthen its breast cancer treatment portfolio.

Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?

Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Genomic Health, Inc. (GHDX) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Genomic Health, Inc. (GHDX).

Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results

The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.

Genomic Health (GHDX) Surpasses Q2 Earnings and Revenue Estimates

Genomic Health (GHDX) delivered earnings and revenue surprises of 20.00% and 2.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Genomic Health (GHDX) to Report Q2 Results: Wall Street Expects Earnings Growth

Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Genomic Health (GHDX) Down 5% Since Last Earnings Report?

Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up

Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.

Genomic Health (GHDX) Q1 Earnings and Revenues Top Estimates

Genomic Health (GHDX) delivered earnings and revenue surprises of 17.24% and 1.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Genomic Health (GHDX) Earnings Expected to Grow: Should You Buy?

Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink

The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink

Genomic Health's New Positive Data to Boost Test Uptake

Genomic Health (GHDX) continues to see positive developments for Oncotype DX Breast Recurrence Score tests.

4 Small Biotech Stocks Likely to Witness More Upside in 2019

The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.

Here's Why You Should Invest in Genomic Health (GHDX) Now

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.

Why Is Genomic Health (GHDX) Down 4.8% Since Last Earnings Report?

Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.